Trial Profile
Tamoxifen versus fenretinide versus tamoxifen + fenretinide in premenopausal women at risk of breast cancer
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2015
Price :
$35
*
At a glance
- Drugs Fenretinide (Primary) ; Tamoxifen (Primary)
- Indications Breast cancer; Early breast cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 06 Apr 2011 Pharmacogenomic results presented at the 102nd Annual Meeting of the American Association for Cancer Research.
- 05 Nov 2010 New trial record.